Novel recent investigations for de novo CML patients have examined the validity of gene expression profiling, genetic polymorphisms, next-generation genomics, multidrug resistance genes (MDR, OCT1), fusion transcripts, and preexisting BCR-ABL kinase domain mutations [34,35,36,37,38,39,40,41,42,43]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.